Merck (MRK) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of WINREVAIR. This medication, in combination with other therapies, is aimed at treating pulmonary arterial hypertension (PAH) in adult patients classified under WHO Functional Class II to III, with the goal of enhancing their exercise capacity. The European Commission is anticipated to make a decision on the marketing authorization application by the third quarter of 2024.
Previously, WINREVAIR received both Priority Medicines and orphan designation status from the EMA for treating pulmonary arterial hypertension. Additionally, the FDA approved WINREVAIR in March 2024.
For further health news, visit rttnews.com.
